desethyloxybutynin has been researched along with oxybutynin in 36 studies
| Studies (desethyloxybutynin) | Trials (desethyloxybutynin) | Recent Studies (post-2010) (desethyloxybutynin) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 38 | 12 | 6 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | desethyloxybutynin (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 22 (61.11) | 29.6817 |
| 2010's | 4 (11.11) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Geraint, M; Gordon, D; Hughes, KM; Lang, JC; Lazare, R; Malone-Lee, J; Stanton, SL | 1 |
| Ericsson, O; Hallström, G; Johansson, C; Lindeke, B; Olsson, LI; Strömberg, S | 1 |
| Andersson, KE; Larsson, B; Waldeck, K | 1 |
| Aranko, K; Hakonen, T; Juhakoski, A; Lukkari, E; Neuvonen, PJ | 1 |
| Aranko, K; Juhakoski, A; Lukkari, E; Neuvonen, PJ | 1 |
| Haarala, M; Hakonen, T; Kiilholma, P; Kivelä, A; Lukkari, E; Nilsson, CG | 1 |
| Aberg, G; Fang, Y; McCullough, JR; Smith, ER; Wright, SE | 1 |
| Aigrain, EJ; Médard, Y; Popon, M; Yaïch, M | 1 |
| Gupta, SK; Sathyan, G | 1 |
| Das, AK; Kay, F; Kogan, BA; Levin, RM; Mahashabde, A; Schröder, A | 1 |
| Feick, A; Quan, D; Sanders, SW; Schmid, B; Zobrist, RH | 1 |
| Capelli, G; Di Stasi, SM; Giannantoni, A; Navarra, P; Porena, M; Stephen, RL; Storti, L | 1 |
| Hakonen, T; Lehtoranta, K; Lukkari-Lax, E; Tainio, H; Tammela, TL | 1 |
| Han, SB; Kim, H | 1 |
| Appell, RA; Chancellor, MB; Sanders, SW; Thomas, H; Zobrist, RH | 1 |
| Bang, LM; Easthope, SE; Perry, CM | 1 |
| Chancellor, M | 1 |
| Wagg, A | 1 |
| Koganei, M; Murata, N; Uchida, M; Yamaji, T | 1 |
| Perry, CM; Scott, LJ; Siddiqui, MA | 1 |
| Koganei, M; Nakajima, M; Uchida, M; Yamaji, T | 1 |
| Miyata, K; Oki, T; Sato, S; Yamada, S | 1 |
| Kawashima, A; Oki, T; Uchida, M; Yamada, S | 1 |
| Oki, T; Toma-Okura, A; Yamada, S | 1 |
| Abe, K; Fukazawa, I; Ishizuka, H; Mizushima, H; Takanaka, K | 1 |
| Darke, AC; Reiz, JL; Salem, P | 1 |
| Abe, K; Ishizuka, H; Kinoshita, K; Mizushima, H; Yamada, Y | 1 |
| Fujino Oki, T; Kato, Y; Kurosawa, S; Nanri, M; Uchida, S; Yamada, S; Yoshida, K | 1 |
| Davila, GW | 1 |
| Gupta, SK; Huang, Y; Parker, MH; Reitz, AB; Ryan, RR | 1 |
| Bonato, PS; da Fonseca, P; de Freitas, LA; Pestana, CR; Pinto, LF | 1 |
| Caramelli, KE; Dmochowski, RR; Hoel, G; Newman, DK; Rudy, DC; Sand, PK; Thomas, H | 1 |
| Berawala, H; Guttikar, S; Patel, DP; Sanyal, M; Sharma, P; Shrivastav, PS | 1 |
| Guttikar, S; Patel, DP; Sanyal, M; Sharma, P; Shrivastav, PS | 1 |
| Qin, F; Sun, J; Tian, Y; Wen, Y; Xiong, Z; Zhao, L | 1 |
| Albrecht, U; Fuhr, U; Krause, P; Kretschmar, M; Rubenwolf, P; Stein, R; Suleiman, AA; Taubert, M | 1 |
1 review(s) available for desethyloxybutynin and oxybutynin
| Article | Year |
|---|---|
Transdermal oxybutynin in the treatment of overactive bladder.
Topics: Administration, Topical; Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Parasympatholytics; Patient Satisfaction; Phenylpropanolamine; Technology, Pharmaceutical; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
12 trial(s) available for desethyloxybutynin and oxybutynin
| Article | Year |
|---|---|
Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet.
Topics: Adult; Cholinergic Antagonists; Delayed-Action Preparations; Eating; Female; Humans; Male; Mandelic Acids; Saliva; Time Factors | 1997 |
Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite.
Topics: Adolescent; Adult; Antifungal Agents; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Method; Drug Synergism; Female; Humans; Itraconazole; Male; Mandelic Acids | 1997 |
Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients.
Topics: Adult; Aged; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Mandelic Acids; Middle Aged; Osmolar Concentration; Tablets; Urinary Incontinence | 1997 |
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Topics: Administration, Oral; Aged; Area Under Curve; Cholinergic Antagonists; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mandelic Acids; Metabolic Clearance Rate; Middle Aged; Urinary Incontinence; Xerostomia | 1999 |
Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Cross-Over Studies; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Skin Absorption; Stereoisomerism | 2001 |
Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Topics: Administration, Intravesical; Adolescent; Adult; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Middle Aged; Urinary Bladder, Neurogenic; Urinary Incontinence; Urodynamics | 2002 |
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analysis of Variance; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Linear Models; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Reference Values; Saliva; Salivation; Time Factors | 2003 |
Transdermal oxybutynin: for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Exanthema; Humans; Mandelic Acids; Middle Aged; Phenylpropanolamine; Time Factors; Tolterodine Tartrate; Urinary Bladder Diseases; Urinary Incontinence; Xerostomia | 2003 |
Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
Topics: Administration, Cutaneous; Adult; Cytochrome P-450 Enzyme System; Female; Humans; Kinetics; Male; Mandelic Acids; Microsomes, Liver; Parasympatholytics; Protein Binding; Stereoisomerism | 2007 |
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Dizziness; Headache; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Nausea; Parasympatholytics; Regression Analysis; Salivation; Tablets; Time Factors; Xerostomia | 2007 |
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Topics: Administration, Cutaneous; Adult; Area Under Curve; Baths; Cholinergic Antagonists; Female; Gels; Humans; Mandelic Acids; Muscarinic Antagonists; Sunscreening Agents; Therapeutic Equivalency; Urinary Bladder, Overactive; Water; Young Adult | 2011 |
A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
Topics: Administration, Intravesical; Administration, Oral; Area Under Curve; Cholinergic Antagonists; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Mandelic Acids; Metabolic Clearance Rate; Models, Biological | 2021 |
23 other study(ies) available for desethyloxybutynin and oxybutynin
| Article | Year |
|---|---|
Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aging; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Frail Elderly; Humans; Intestinal Absorption; Male; Mandelic Acids | 1992 |
Metabolism of Oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis.
Topics: Animals; Chemical Phenomena; Chemistry; Gas Chromatography-Mass Spectrometry; Male; Mandelic Acids; Microsomes, Liver; Rats; Rats, Inbred Strains | 1981 |
Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.
Topics: Adult; Aged; Atropine; Carbachol; Humans; In Vitro Techniques; Mandelic Acids; Middle Aged; Muscarinic Agonists; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Parotid Gland; Receptors, Muscarinic; Urinary Bladder | 1997 |
Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline.
Topics: Animals; Butylamines; Carbachol; Guinea Pigs; In Vitro Techniques; Isometric Contraction; Male; Mandelic Acids; Muscle, Smooth; Parasympatholytics; Potassium; Stereoisomerism; Structure-Activity Relationship; Urinary Bladder | 1998 |
In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans.
Topics: Aryl Hydrocarbon Hydroxylases; Cholinergic Antagonists; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Mandelic Acids; Microsomes, Liver; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 1998 |
Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder.
Topics: Absorption; Administration, Intravaginal; Animals; Compliance; Delayed-Action Preparations; Female; Mandelic Acids; Parasympatholytics; Rabbits; Silicone Elastomers; Urinary Bladder; Vagina | 2000 |
Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
Topics: Administration, Intravesical; Adolescent; Adult; Cholinergic Antagonists; Diffusion; Electrochemistry; Female; Humans; Male; Mandelic Acids; Middle Aged; Urinary Bladder, Neurogenic; Urodynamics | 2001 |
Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS.
Topics: Animals; Cholinergic Antagonists; Chromatography, Liquid; Dogs; Mandelic Acids; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Erythema; Humans; Mandelic Acids; Pruritus; Urinary Bladder Diseases; Urinary Incontinence | 2003 |
Transdermal oxybutynin. A viewpoint by Adrian Wagg.
Topics: Administration, Cutaneous; Adult; Aged; Delayed-Action Preparations; Humans; Mandelic Acids; Skin; Urinary Bladder Diseases; Urinary Incontinence | 2003 |
Effects of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride, a metabolite of oxybutynin, on bladder specimens and rhythmic bladder contraction in rats in comparison with oxybutynin.
Topics: Animals; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mandelic Acids; Muscle Contraction; Rats; Rats, Sprague-Dawley; Urinary Bladder | 2004 |
Oxybutynin extended-release: a review of its use in the management of overactive bladder.
Topics: Administration, Oral; Animals; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mandelic Acids; Multicenter Studies as Topic; Prodrugs; Randomized Controlled Trials as Topic; Retrospective Studies; Stereoisomerism; Urination Disorders | 2004 |
[Effect of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl) glycolate, metabolite of oxybutynin, on intra-artery administered acetylcholine-induced urinary bladder contraction in anesthetized dogs].
Topics: Acetylcholine; Anesthesia; Animals; Confidence Intervals; Dogs; Dose-Response Relationship, Drug; Female; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Pressure; Urinary Bladder | 2004 |
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Topics: Administration, Oral; Animals; Depression, Chemical; In Vitro Techniques; Male; Mandelic Acids; Mice; Muscarinic Antagonists; Quinuclidines; Radioligand Assay; Receptors, Muscarinic; Salivary Glands; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2005 |
In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
Topics: Analysis of Variance; Animals; Cholinergic Antagonists; Colon; Dose-Response Relationship, Drug; Injections, Intravenous; Male; Mandelic Acids; Muscarinic Antagonists; Myocardium; N-Methylscopolamine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Saliva; Submandibular Gland; Time Factors; Urinary Bladder | 2005 |
Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Male; Mandelic Acids; N-Methylscopolamine; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Saliva; Urinary Bladder Diseases | 2006 |
Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Cholinergic Antagonists; In Vitro Techniques; Injections, Intravenous; Male; Mandelic Acids; Muscle Contraction; Muscle, Smooth; Pressure; Rats; Rats, Inbred Strains; Receptors, Cholinergic; Stereoisomerism; Transducers, Pressure; Urinary Bladder | 2007 |
Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
Topics: Analysis of Variance; Animals; Benzilates; Brain; Calcium Channels, L-Type; Diltiazem; Isradipine; Male; Mandelic Acids; N-Methylscopolamine; Protein Binding; Rats; Rats, Sprague-Dawley; Tritium; Urinary Bladder; Verapamil | 2007 |
The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Receptor, Muscarinic M4; Receptor, Muscarinic M5; Receptors, Muscarinic; Stereoisomerism; Structure-Activity Relationship; Urinary Incontinence | 2007 |
Enantioselective analysis of oxybutynin and N-desethyloxybutynin with application to an in vitro biotransformation study.
Topics: Animals; Biotransformation; Chemical Fractionation; Male; Mandelic Acids; Microsomes, Liver; Rats; Rats, Wistar; Stereoisomerism | 2008 |
Simultaneous analysis of oxybutynin and its active metabolite N-desethyl oxybutynin in human plasma by stable isotope dilution LC-MS/MS to support a bioequivalence study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Indicator Dilution Techniques; Liquid-Liquid Extraction; Mandelic Acids; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Parallel achiral-chiral determination of oxybutynin, N-desethyl oxybutynin and their enantiomers in human plasma by LC-MS/MS to support a bioequivalence trial.
Topics: Blood Chemical Analysis; Calibration; Chromatography; Chromatography, Liquid; Drug Stability; Healthy Volunteers; Humans; India; Liquid-Liquid Extraction; Mandelic Acids; Pilot Projects; Quality Control; Reproducibility of Results; Solvents; Stereoisomerism; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2014 |
Simultaneous quantification of oxybutynin and its active metabolite N-desethyl oxybutynin in rat plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of oxybutynin transdermal patch
Topics: Animals; Chromatography, High Pressure Liquid; Limit of Detection; Linear Models; Male; Mandelic Acids; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Transdermal Patch | 2019 |